Expression and Activity Profiles of DPP IV/CD26 and NEP/CD10 Glycoproteins in the Human Renal Cancer Are Tumor-type Dependent

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 May 13

PMID 20459800

Citations 26

Authors

Adolfo Varona

Lorena Blanco

Itxaro Perez

Javier Gil

Jon Irazusta

Jose I Lopez

M Luz Candenas

Francisco M Pinto

Gorka Larrinaga

Affiliations

Soon will be listed here.

Abstract

Background: Cell-surface glycoproteins play critical roles in cell-to-cell recognition, signal transduction and regulation, thus being crucial in cell proliferation and cancer etiogenesis and development. DPP IV and NEP are ubiquitous glycopeptidases closely linked to tumor pathogenesis and development, and they are used as markers in some cancers. In the present study, the activity and protein and mRNA expression of these glycoproteins were analysed in a subset of clear-cell (CCRCC) and chromophobe (ChRCC) renal cell carcinomas, and in renal oncocytomas (RO).

Methods: Peptidase activities were measured by conventional enzymatic assays with fluorogen-derived substrates. Gene expression was quantitatively determined by qRT-PCR and membrane-bound protein expression and distribution analysis was performed by specific immunostaining.

Results: The activity of both glycoproteins was sharply decreased in the three histological types of renal tumors. Protein and mRNA expression was strongly downregulated in tumors from distal nephron (ChRCC and RO). Moreover, soluble DPP IV activity positively correlated with the aggressiveness of CCRCCs (higher activities in high grade tumors).

Conclusions: These results support the pivotal role for DPP IV and NEP in the malignant transformation pathways and point to these peptidases as potential diagnostic markers.

Citing Articles

DPP4, a potential tumor biomarker, and tumor therapeutic target: review.

Sun L, Ma Y, Geng C, Gao X, Li X, Ru Q Mol Biol Rep. 2025; 52(1):126.

PMID: 39821530 DOI: 10.1007/s11033-025-10235-6.

Preclinical Repurposing of Sitagliptin as a Drug Candidate for Colorectal Cancer by Targeting //-Centered Signaling Hub.

Shih J, Wu A, Mokgautsi N, Wei P, Huang Y Int J Mol Sci. 2024; 25(1).

PMID: 38203779 PMC: 10778938. DOI: 10.3390/ijms25010609.

Renal cancer secretome induces migration of mesenchymal stromal cells.

Poplawski P, Zarychta-Wisniewska W, Burdzinska A, Boguslawska J, Adamiok-Ostrowska A, Hanusek K Stem Cell Res Ther. 2023; 14(1):200.

PMID: 37563650 PMC: 10413545. DOI: 10.1186/s13287-023-03430-4.

Multiomics surface receptor profiling of the NCI-60 tumor cell panel uncovers novel theranostics for cancer immunotherapy.

Heumos S, Dehn S, Brautigam K, Codrea M, Schurch C, Lauer U Cancer Cell Int. 2022; 22(1):311.

PMID: 36221114 PMC: 9555072. DOI: 10.1186/s12935-022-02710-y.

Roles of ferroptosis in urologic malignancies.

Zhao S, Li P, Wu W, Wang Q, Qian B, Li X Cancer Cell Int. 2021; 21(1):676.

PMID: 34922551 PMC: 8684233. DOI: 10.1186/s12935-021-02264-5.

References

Rozen S, Skaletsky H . Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 1999; 132:365-86. DOI: 10.1385/1-59259-192-2:365. View

Kikkawa F, Kajiyama H, Shibata K, Ino K, Nomura S, Mizutani S . Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta. 2005; 1751(1):45-51. DOI: 10.1016/j.bbapap.2004.09.028. View

Larrinaga G, Lopez J, Casis L, Blanco L, Gil J, Agirregoitia E . Cystinyl aminopeptidase activity is decreased in renal cell carcinomas. Regul Pept. 2007; 144(1-3):56-61. DOI: 10.1016/j.regpep.2007.06.002. View

Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z . 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006; 49(5):798-805. DOI: 10.1016/j.eururo.2005.11.035. View

Fuhrman S, Lasky L, Limas C . Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6(7):655-63. DOI: 10.1097/00000478-198210000-00007. View

Droz D, Zachar D, Charbit L, Gogusev J, Chretein Y, IRIS L . Expression of the human nephron differentiation molecules in renal cell carcinomas. Am J Pathol. 1990; 137(4):895-905. PMC: 1877557. View

Liu W, Hansen P . Progesterone-induced secretion of dipeptidyl peptidase-IV (cluster differentiation antigen-26) by the uterine endometrium of the ewe and cow that costimulates lymphocyte proliferation. Endocrinology. 1995; 136(2):779-87. DOI: 10.1210/endo.136.2.7835310. View

Patak E, Candenas M, Pennefather J, Ziccone S, Lilley A, Martin J . Tachykinins and tachykinin receptors in human uterus. Br J Pharmacol. 2003; 139(3):523-32. PMC: 1573878. DOI: 10.1038/sj.bjp.0705279. View

Jin J, Hsieh D, Lin Y, Wang J, Sheu L, Lee W . Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol. 2006; 13(5):573-80. DOI: 10.1111/j.1442-2042.2006.01353.x. View

10.

Sumitomo M, Shen R, Nanus D . Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta. 2005; 1751(1):52-9. DOI: 10.1016/j.bbapap.2004.11.001. View

11.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M . Cancer statistics, 2007. CA Cancer J Clin. 2007; 57(1):43-66. DOI: 10.3322/canjclin.57.1.43. View

12.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

13.

Martignoni G, Pea M, Brunelli M, Chilosi M, Zamo A, Bertaso M . CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol. 2004; 17(12):1455-63. DOI: 10.1038/modpathol.3800236. View

14.

Goodman Jr O, Febbraio M, Simantov R, Zheng R, Shen R, Silverstein R . Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. J Biol Chem. 2006; 281(44):33597-605. DOI: 10.1074/jbc.M602490200. View

15.

Papandreou C, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S . Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med. 1998; 4(1):50-7. DOI: 10.1038/nm0198-050. View

16.

Zhou M, Roma A, Magi-Galluzzi C . The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med. 2005; 25(2):247-57. DOI: 10.1016/j.cll.2005.01.004. View

17.

Gohring B, Holzhausen H, Meye A, Heynemann H, Rebmann U, Langner J . Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. Int J Mol Med. 1998; 2(4):409-14. DOI: 10.3892/ijmm.2.4.409. View

18.

Avery A, Beckstead J, Renshaw A, Corless C . Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000; 24(2):203-10. DOI: 10.1097/00000478-200002000-00006. View

19.

Raguin O, Fournie-Zaluski M, Romieu A, Pelegrin A, Chatelet F, Pelaprat D . A labeled neutral endopeptidase inhibitor as a potential tool for tumor diagnosis and prognosis. Angew Chem Int Ed Engl. 2005; 44(26):4058-61. DOI: 10.1002/anie.200500700. View

20.

Cordero O, Ayude D, Nogueira M, Rodriguez-Berrocal F, de la Cadena M . Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer. 2000; 83(9):1139-46. PMC: 2363587. DOI: 10.1054/bjoc.2000.1410. View